Leriglitazone is an oral selective peroxisome proliferator-activated receptor gamma agonist indicated for cerebral adrenoleukodystrophy in males aged 2 to 12 years with non-gadolinium-enhancing brain lesions and a Neurological Functional Score of 0 or 1. The European Commission granted marketing authorization for leriglitazone under exceptional circumstances on September 21, 2026, for cALD in male patients aged 2 to 12 years with non-gadolinium-enhancing brain lesions and a Neurological Functional Score of...
- Mechanism
- Curator reviewed · 4 references
Leriglitazone is a selective PPARγ agonist. In in vitro models of cALD, it decreased neuroinflammation through inhibition of NF-κB-mediated inflammatory signaling, protected neurons and astrocytes, and reduced microglia activation. It also reduced oxidative stress and promoted mitochondrial function in neural cell types, and decreased monocyte adhesion to endothelial cells in blood-brain barrier models. Protective and restorative effects on myelination have been demonstrated in both in vitro and in vivo models.
- Primary indication
- European Union Leriglitazone is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non-Gadolinium (Gd) enhancing lesions (i.e.Curator reviewed · 1 structured indication
- Formula / weight
- C19H20N2O4S · 372.438 g/mol (avg)
- Also known as
- Hydroxypioglitazone
- Code names
- MIN-102
Resolves to
OXVFDZYQLGRLCD-UHFFFAOYSA-NSMILESCC(O)C1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1What you can answer from here — as of October 28, 2026
Which drugs share a target with Leriglitazone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account